Skip to main content
. 2024 Oct 6;18(5):183–198. doi: 10.1049/syb2.12099

FIGURE 11.

FIGURE 11

Chemosensitivity analysis. (a) sorafenib; (b) sunitinib; (c) dasatinib; (d) imatinib; (e) paclitaxel; and (f) doxorubicin.